Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2021 Mar 3:2021:7341247.
doi: 10.1155/2021/7341247. eCollection 2021.

Serum Levels of S100A11 and MMP-9 in Patients with Epithelial Ovarian Cancer and Their Clinical Significance

Wenjing Li  1 , Zhumei Cui  2 , Yan Kong  1 , Xiangyu Liu  1 , Xiangyu Wang  1
Affiliations
Clinical Trial

Serum Levels of S100A11 and MMP-9 in Patients with Epithelial Ovarian Cancer and Their Clinical Significance

Wenjing Li et al. Biomed Res Int. .

Abstract

Objective: To investigate the serum levels of calgizzarin (S100A11) and matrix metalloproteinase-9 (MMP9) in patients with epithelial ovarian cancer (EOC) and determine their clinical significance.

Methods: Serum levels of S100A11 and MMP9 were detected in patients with EOC, patients with benign ovarian tumor, and healthy women. The correlation between the two markers and clinicopathological characteristics of ovarian cancer was analysed.

Results: The serum levels of S100A11 and MMP-9 in patients with EOC were higher than those in patients with benign ovarian tumor and in healthy women, and the expression levels of S100A11 and MMP-9 were positively correlated. S100A11 and MMP-9 were correlated with tumor staging, postoperative residual foci, ascites volume, serum CA125 level, chemotherapy response, and lymph node metastasis, while S100A11 and MMP-9 were not associated with the bilevel classification, histological type, age, and degree of differentiation.

Conclusion: S100A11 and MMP-9 were both highly expressed in the serum of patients with EOC and were associated with cancer development, invasion, and metastasis. Therefore, they can be used as an important reference maker in the diagnosis and treatment of ovarian cancer.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests.

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Mirandola L., Cannon J. M., Cobos E., et al. Cancer testis antigens: novel biomarkers and targetable proteins for ovarian cancer. International Reviews of Immunology. 2011;30(2-3):127–137. doi: 10.3109/08830185.2011.572504. - DOI - PubMed
    1. Ignacio R., Bast R. C. Minireview: human ovarian cancer: biology, current management, and paths to personalizing therapy. Endocrinology. 2012;153:1593–1602. - PMC - PubMed
    1. Koh S. A., Lee K. H. HGF-mediated S100A11 overexpression enhances proliferation and invasion of gastric cancer. American Journal of Translational Research. 2018;10:3385–3394. - PMC - PubMed
    1. Kessenbrock K., Plaks V., Werb Z. Matrix metalloproteinases: regulators of the tumor microenvironment. Cell. 2010;141(1):52–67. doi: 10.1016/j.cell.2010.03.015. - DOI - PMC - PubMed
    1. Li Y., Zhang J. Expression of S100A11 is a prognostic factor for disease-free survival and overall survival in patients with high-grade serous ovarian cancer. Applied Immunohistochemistry & Molecular Morphology. 2015;25(2):110–116. - PubMed

Publication types